As soon as information is available, Tam Anh General Hospital is the pioneer to introduce anti-Evusheld monoclonal antibodies COVID-19 of AstraZeneca – the world’s leading pharmaceutical company in Vietnam, every day, the hospital’s switchboard system, fanpage, and website receive thousands of calls and messages asking about monoclonal antibodies, especially those with diseases Background such as hypertension, cirrhosis, chronic kidney failure, cardiovascular disease, cancer… Because this is a group of people who are susceptible to weakened resistance and are at risk of severe illness and death when infected with COVID-19.
Assoc. Prof. TS.BS Tran Quang Binh – Professional Director of Tam Anh General Hospital in Ho Chi Minh City shared: “Evusheld is the world’s first monoclonal antibody against COVID-19 that has been approved for emergency use by the FDA (USA) and approved by the FDA. Urgent approval by many countries around the world to promptly protect vulnerable populations from COVID-19, especially as the Omicron variant is spreading.
The monoclonal antibody Evusheld is licensed for circulation in emergency situations in a number of countries such as the US, France, the United Arab Emirates, Bahrain… With the support of the Ministry of Health, AstraZeneca Vietnam, The system of Tam Anh General Hospital is lucky to be able to bring back this powerful “weapon” to Vietnam to protect the vulnerable group.
The World Health Organization (WHO), estimates that about 2% of the global population is vulnerable to COVID-19 due to moderate and severe immunodeficiency such as HIV, cancer, organ transplantation (heart transplant, liver transplant, kidney transplant), high-dose, long-term corticosteroid use…
In Vietnam, according to statistics of the Ministry of Health, the whole country currently has nearly 230,000 people infected with HIV (in 2021 alone, 13,223 were detected, Ho Chi Minh City accounts for 26%); 6,100 organ transplants (5,700 kidney transplants accounted for nearly 94%, 316 liver transplants more than 5%…); Cancer has 182,563 new cases and 122,690 deaths (100,000 people, 159 new cases and 106 cancer deaths)… Therefore, the monoclonal antibody Evusheld was licensed to Vietnam at that time. This point has profound human meaning.
Because the weak group needs an extra shield to protect health before the SARS-CoV-2 variants are spreading while it is difficult to have a good immune response, despite having received a full dose of vaccine, even a booster dose. Many countries around the world are expecting that Evusheld will help disadvantaged groups to overcome the COVID-19 storm.
Evusheld monoclonal antibody does not replace the COVID-19 vaccine for the community, but only targets people who are immunocompromised or are unable to have a satisfactory immune response, or do not produce adequate antibodies after vaccination. full dose of vaccine and for people who are unable to receive the vaccine because of a serious adverse reaction to the COVID-19 vaccine.
It is also difficult for countries to spend budget to buy Evusheld to vaccinate people. Even the US has posted information that the government is at risk of running out of funds to support the purchase of Evusheld for patients vaccinated against COVID-19. Up to 7 million Americans are currently moderately or severely immunocompromised, and millions more are elderly with underlying medical conditions.
The US Congress needed to spend $22.5 billion to buy Evusheld, but the federal government was no longer able to receive funding to buy monoclonal antibodies, forcing more than 30% of the previously budgeted allocation from Congress. Therefore, in the coming time, the US Government can only buy enough treatment for 850,000 people.
Previously, the US ordered 1.7 million doses of Evusheld, of which 1.2 million doses will be distributed in the first 6 months of the year, and 500,000 doses will be distributed in the last 6 months of the year. With no new federal funding, the US will likely run out of Evosheld by the end of the year.
Many experts said that if the plan to buy Evusheld is stopped, the risk of the COVID-19 pandemic will continue to spread in a new wave. The US has spent nearly 6 trillion dollars on pandemic relief and will certainly pay the price many times over if it is not invested in buying Evosheld.
Assoc. Prof. TS.BS Tran Quang Binh said that the monoclonal antibody Evusheld needs to meet the criteria such as being 12 years old or older, weighing 40 kg and not being infected with SARS-CoV-2 at the time of injection and have not had contact with a confirmed SARS-CoV-2 infected person, and must be in one of the following cases:
- Moderate to severe immunosuppression due to a medical condition, or use of immunosuppressive drugs or regimens, and likely failure to induce an adequate immune response to the COVID-19 vaccine.
- Can’t inject any kind COVID-19 vaccine are available because of a history of serious adverse events (eg, severe allergy) with any component of the COVID-19 vaccine.
As recommended by the manufacturer of AstraZeneca, the FDA, and the Department of Health, medical conditions or treatments that may lead to moderate to severe immunodeficiency and an inadequate immune response to the COVID vaccine -19 includes but is not limited to:
- Ongoing treatment for solid tumors and hematological malignancies. Organ transplant and currently receiving immunosuppressive therapy.
- Reception of mosaic antigen receptor (CAR)-T lymphocytes or hematopoietic stem cell transplantation (within 2 years after transplantation or on immunosuppressive therapy).
- Moderate to severe primary immunodeficiency (eg, DiGeorge syndrome, Wiskott-Aldrich syndrome).
- Advanced or untreated HIV infection (people with HIV with a CD4 cell count
- Active treatment with high-dose corticosteroids (ie, ≥20 mg prednisone or equivalent daily when administered for ≥ 2 weeks), alkylating agents, anti-metabolites, transplant-related immunosuppressants, cancer chemotherapy agents classified as severe immunosuppressants, tumor necrosis factor (TNF) inhibitors, and other biological agents with immunosuppressive or immunomodulatory effects ( eg, B-cell inhibitor).
Evusheld is a monoclonal antibody researched and manufactured by pharmaceutical company AstraZeneca (United Kingdom – Sweden), which has provided hundreds of millions of doses of COVID-19 vaccine globally.
From more than 1,500 antibodies from people recovering from COVID-19 around the world, scientists have selected the two most potent antibodies to create Evosheld. This is the world’s first COVID-19 prophylactic monoclonal antibody approved by the FDA.
The monoclonal antibody Evusheld is licensed by the Ministry of Health for Tam Anh General Hospital System to import and use through the distribution of Vietnam Vaccine Company (VNVC) and AstraZeneca Company.
To register for injection of Evusheld monoclonal antibodies at Tam Anh Hanoi General Hospital System and Tam Anh General Hospital in Ho Chi Minh City; Customers register at the link: https://tamanhhospital.vn/dang-ky-tiem-evusheld/
Or you can contact the Customer Care Department through the official information channels of Tam Anh General Hospital System:
- Information Call Center: 0287 102 6789 (HCMC); 1800 6858 (Hanoi City)
- Website information: https://tamanhhospital.vn
- Information Fanpage: https://www.facebook.com/benhvientamanh
at Blogtuan.info – Source: vtc.vn – Read the original article here